Patients receiving continuous bevacizumab accrued higher total costs ( +599 ( $ 938 ) ; 95 % CI 91 to 1107 ; p = 0.021 ) than those receiving discontinuous bevacizumab , but also accrued non-significantly more QALYs ( +0.020 ; 95 % CI -0.032 to 0.071 ; p = 0.452 ) .